Biosimilars and Patent Expirations Reshape Biologic Drug Lifecycle Management

Biosimilars are increasingly influencing the management of biologic drug lifecycles, according to a recent analysis. The report highlights the role of biosimilars in driving down costs and increasing competition within the biologics market. In addition, the expiration of patents, also known as patent cliffs, are presenting significant challenges for biologic drug manufacturers. The analysis indicates that as biosimilar competition intensifies, life cycle management strategies are changing. Specifically, biosimilars are contributing to a more competitive landscape for biologic drugs because they provide more competition in the market, thus driving down the costs. In addition, biologic manufacturers now must face expiring patents which is also changing their strategies.

Newsflash | Powered by GeneOnline AI
Date: April 7, 2025

Related posts:

PepGen’s New Drug Candidate Shows Promising Results in Treating Rare Muscle Disorder Trodelvy and Keytruda Combination Therapy Delays Tumor Growth in Aggressive Breast Cancer Study Harvard Sues Trump Administration: Alleges First Amendment Violation Over Research Funding Freeze. Social Media Use Tied to Self-Esteem in Teens; Girls Spending Over Three Hours Daily on Image-Focused Platforms Report Lower Self-Worth.

Author

Mark Chiang